Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vifor gets exclusive rights to Isotechnika's voclosporin for lupus and nephrology indications

Executive Summary

Isotechnika Inc. (immunomodulating therapies) has granted Vifor Pharma Ltd., the drug business of Galenica Group, exclusive worldwide rights to its lead compound voclosporin for lupus and all proteinuric nephrology indications. The license specifically includes the US, but excludes territories already held by Paladin (Canada, South Africa, and Israel), and 3SBio (China, Taiwan, and Hong Kong).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register